Recent Updates
Recently added Catalysts
PHGE Positive Sentiment

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

Monday, March 27, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BiomX Inc., a clinical-stage company specializing in phage therapies, has announced a conference call scheduled for March 29th, 2023. During this call, they will report their fourth quarter and full year 2022 financial results along with providing business updates. BiomX focuses on developing treatments for chronic diseases by targeting specific pathogenic bacteria through natural and engineered phage compositions.
Price reaction · baseline $58.938 (2023-03-24 close) · 1 other PHGE headline(s) in the window, move may be shared
day 0 close · peak
+7%
day 1
+0.9%
day 3
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • BiomX is advancing novel phage therapies that target specific pathogenic bacteria.
  • The conference call provides an opportunity to share financial results and business updates.
  • The company's focus on chronic diseases showcases innovative approaches in treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+190%
120-day peak, hindsight
Typical move
13.4%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
BX002-A
Phase 1 · Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 29th, 2023, at 8:00 a.m. ET, to report fourth quarter and full year 2022 financial results and provide business updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Corporate Project Manager

Frequently Asked Questions

When will BiomX's conference call take place?

The conference call is scheduled for March 29, 2023, at 8:00 a.m. ET.

How can I listen to the BiomX conference call?

Participants can dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International).

What is BiomX developing in the biopharma sector?

BiomX is developing natural and engineered phage therapies targeting pathogenic bacteria.

Where can I find more information about BiomX?

More information is available on BiomX's official website, www.biomx.com.

ShareAdd on Google
Tags: PHGE Viatris Investor Conferences Healthcare BiomX phage therapies financial results chronic diseases
Last updated: Mar 27, 2023

Biotech snapshot

Cash runway
$1M liquidity · $0M/mo burn
~1 mo
High dilution risk
Lead asset
BX002-APhase 1
Healthy Volunteers →

Catalyst track record

+190%
best trade around PHGE's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PHGE.

See every catalyst's timing & PoA →